Julianna Lisziewicz | Academic Influence

Why Is Julianna Lisziewicz Influential?

According to Wikipedia, Julianna Lisziewicz is a Hungarian immunologist. Lisziewicz headed many research teams that have discovered and produced immunotheraputic drugs to treat diseases like cancer and chronic infections like HIV/AIDS. Some of these drugs have been successfully used in clinical trials.

(See a Problem?)

Julianna Lisziewicz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy (1999) (2106)
Control of HIV despite the discontinuation of antiretroviral therapy. (1999) (359)
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. (1994) (314)
Control of SIV rebound through structured treatment interruptions during early infection. (2000) (195)
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. (1993) (127)
Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. (1994) (112)
Structured treatment interruptions for the management of HIV infection. (2001) (111)
Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. (1992) (105)
Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. (1997) (94)
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. (1999) (94)
Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. (1993) (92)
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. (1997) (92)
DermaVir: a novel topical vaccine for HIV/AIDS. (2005) (87)
Structured treatment interruptions to control HIV-1 infection (2000) (84)
Control of viral rebound through therapeutic immunization with DermaVir (2005) (74)
Single DermaVir Immunization: Dose-Dependent Expansion of Precursor/Memory T Cells against All HIV Antigens in HIV-1 Infected Individuals (2012) (63)
Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotides (1994) (60)
Isolation and nucleotide sequence of a Saccharomyces cerevisiae protein kinase gene suppressing the cell cycle start mutation cdc25. (1987) (55)
Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells (2001) (55)
Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. (1999) (51)
Antitat gene therapy: a candidate for late-stage AIDS patients. (1995) (50)
Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial (2013) (50)
Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. (1994) (49)
Long-term suppression of HIV-1 by hydroxyurea and didanosine. (1997) (49)
HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor (1998) (47)
Nanomedicine applications towards the cure of HIV. (2013) (47)
HIV-1-Specific T Cell Precursors with High Proliferative Capacity Correlate with Low Viremia and High CD4 Counts in Untreated Individuals1 (2008) (45)
Nanochemistry-based immunotherapy for HIV-1. (2007) (44)
Rational development of a stable liquid formulation for nanomedicine products. (2010) (43)
Structured treatment interruptions in HIV/AIDS therapy. (2002) (42)
IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. (2008) (41)
Transduction of CD34+ hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection (1997) (41)
HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. (2007) (40)
Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element (1993) (40)
Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. (1991) (40)
Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. (2000) (38)
DermaVir, a novel HIV immunisation technology. (2005) (37)
An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy (1995) (37)
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. (2011) (36)
Cloning and characterization of the Saccharomyces cerevisiae CDC6 gene. (1988) (36)
A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. (1994) (35)
Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses (2002) (34)
Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). (1999) (33)
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (‘virostatic’) mechanisms (2005) (32)
Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine. (1997) (31)
Cytokine-adjuvanted HIV-DNA vaccination strategies (2006) (31)
Therapeutic vaccination for future management of HIV/AIDS. (2003) (30)
Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. (1994) (28)
Structure and biological activity of pathogen-like synthetic nanomedicines. (2012) (28)
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. (1999) (27)
Calcium Uptake and Protein Phosphorylation in Myenteric Neurons, Like the Release of Vasoactive Intestinal Polypeptide and Acetylcholine, Are Frequency Dependent (1989) (27)
Vaccination of Mice Using the West Nile Virus E-Protein in a DNA Prime-Protein Boost Strategy Stimulates Cell-Mediated Immunity and Protects Mice against a Lethal Challenge (2014) (26)
Hydroxyurea in the Treatment of HIV Infection (2003) (26)
Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. (1999) (25)
Complementary Antiviral Efficacy of Hydroxyurea and Protease Inhibitors in Human Immunodeficiency Virus-Infected Dendritic Cells and Lymphocytes (2002) (24)
Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. (1996) (23)
Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. (2002) (23)
A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. (2011) (23)
Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys. (1996) (20)
Strategies to Decrease Viral Load Rebound, and Prevent Loss of Cd4 and Onset of Resistance during Structured Treatment Interruptions (2004) (19)
Antisense phosphorothioate oligodeoxynucleotides alter HIV type 1 replication in cultured human macrophages and peripheral blood mononuclear cells. (1995) (19)
The potential of topical DNA vaccines adjuvanted by cytokines (2007) (19)
SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters (2001) (19)
Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. (1999) (17)
Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes (2005) (17)
Safety of hydroxyurea in the treatment of HIV infection (2004) (17)
Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. (2007) (17)
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. (2005) (17)
Hydroxyurea: mechanisms of HIV-1 inhibition. (1998) (16)
Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes (2014) (16)
New Uses for Old Drugs in HIV Infection (2012) (15)
Gene Therapy Approaches to HIV Infection (2002) (14)
Inhibition of HIV-1 replication in chronically infected cell lines and peripheral blood mononuclear cells by retrovirus-mediated antitat gene transfer (2000) (14)
Virostatics: a new class of anti-HIV drugs. (2007) (14)
"Virostatics" as a potential new class of HIV drugs. (2004) (14)
T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection. (2004) (13)
Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule. (2000) (13)
Effects of hydroxyurea on T cell count changes during primary HIV infection. (2000) (13)
Topical DermaVir vaccine targeting dendritic cells. (2006) (12)
Vaccinia assay for the rapid detection of functional HIV-specific CD8+ cytotoxic T lymphocytes. (2003) (12)
Vaccine-Induced Protection of Rhesus Macaques against Plasma Viremia after Intradermal Infection with a European Lineage 1 Strain of West Nile Virus (2014) (12)
APC-targeted immunization for the treatment of HIV-1 (2004) (12)
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine. (1998) (12)
High efficiency lentiviral gene delivery in non‐dividing cells by deoxynucleoside treatment (2002) (11)
Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals. (1999) (9)
A checkpoint in the cell cycle progression as a therapeutic target to inhibit HIV replication. (2007) (9)
Efficacy of antitat gene therapy in the presence of high multiplicity infection and inflammatory cytokines. (1996) (7)
Quantification of HIV-specific CD8 T cells by in vitro stimulation with inactivated viral particles (2002) (7)
DermAll nanomedicine for allergen-specific immunotherapy. (2013) (7)
TAR decoys and trans-dominant gag mutant for HIV-1 gene therapy. (1996) (6)
Rational Design of Formulated DNA Vaccines: The DermaVir Approach (2012) (6)
Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea. (1999) (6)
Low ozone concentration and negative ions for rapid SARS-CoV-2 inactivation (2021) (6)
A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO). (2019) (5)
Immunological approaches for HIV therapy. (2003) (5)
Role of immune modulation in primary HIV infection. (2000) (5)
Precision COVID-19 Vaccine with Companion Diagnostics (2020) (5)
lymphocytes correlates with reduced viral plasma RNA after primary HIV infection (1999) (5)
DNA nanoparticles with core-shell morphology. (2014) (4)
Unsung Hero Robert C. Gallo (2009) (4)
Cellular factors: targets for the treatment of HIV infection. (1998) (4)
Short Communication: Methods of Using Interleukin 2 to Enhance HIV-Specific Immune Responses (2002) (3)
Immune reconstitution and control of HIV. (2004) (3)
The Janus face of immune stimulation by nanomedicines: Examples for the good and the bad (2010) (3)
Nanophysiology: The Janus Face of Immune Stimulation by Nanomedicines: Examples for the Good and the Bad (2010) (3)
Prediction the clinical outcomes of cancer patients after peptide vaccination. (2019) (3)
Gamma/delta T cells (2003) (2)
Targeting HIV reservoirs and reconstituting the immune system. Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC. (1999) (2)
HIV-specific immunotherapy with DermaVir, the first pDNA/PEIm pathogen-like nanomedicine (2012) (2)
Characterization of Nanoparticle Uptake by Epidermal Langerhans Cells in eGFP Langerin Knock in Mice by Multiphoton Laser Scanning Microscopy in vivo (2013) (2)
Gene therapy for HIV-1 (2001) (2)
Role of hydroxyurea during structured treatment interruptions. (2002) (2)
Methods of using interleukin 2 to enhance HIV-specific immune responses. (2002) (2)
Conference scene--active immunotherapeutics forum: meeting highlights. (2009) (1)
Preventive Nanomedicine: Nanomedicine for dendritic cell-targeted immunotherapy (2010) (1)
Transcriptional regulatory elements of the RAS2 gene of Saccharomyces cerevisiae. (1990) (1)
Dermall Nanomedicine for Allergen-Specific Immunotherapy (ASIT) (2013) (1)
Control of the Cell Cycle Start by Protein Kinase Genes in Saccharomyces Cerevisiae (1988) (1)
CD4+ T cell-mediated presentation of non-infectious HIV-1 virion antigens to HIV-specific CD8+ T cells. (2006) (1)
Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients (2022) (1)
Determination of the immunogenetic risk of developing cancer. (2019) (1)
Abstracts of the International Symposium on Molecular Diagnostics and Skin Gene Therapy (2003) (1)
Nanomedicine and HIV/AIDS (2014) (1)
Gene therapy for HIV-1 infection and AIDS (1997) (1)
Compositions for the delivery of genes in antigen-presenting cells of the skin (1998) (0)
Long-term treatment ofhumanimmunodeficiency virus-infected cells withantisense oligonucleotide phosphorothioates (1993) (0)
Human model to predict the outcome of cancer vaccine clinical trials. (2019) (0)
T-lymphocytes with high proliferative capacity correlate with control of viral suppression in chronically untreated HIV-1 infected individual (2007) (0)
Formulation development of a pDNA-based nanomedicine (2013) (0)
Viremia and High CD4 Counts in Untreated Proliferative Capacity Correlate with Low HIV-1-Specific T Cell Precursors with High (2008) (0)
Immunotherapy of HIV Disease (2005) (0)
Vaccination therapeutique a adn (2002) (0)
Viremia and High CD 4 Counts in Untreated Proliferative Capacity Correlate with Low HIV-1-Specific T Cell Precursors with High Tsoukas (2008) (0)
Initial evaluation of oncoretroviral vectors carrying HIV-1 inhibitor gene into rhesus CD34+ cells and/or CD4+ T cells: An in vivo model for the gene therapy of AIDS (2008) (0)
Intracellular immunization against HIV-1 by poly-TAR RNA elements (1991) (0)
A graphical scheme with a timeline of the mice experiments. (2014) (0)
Cloning and characterization of the Saccharomyces cerevisiae CDC 6 gene (2005) (0)
AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs): A New Class of Antiviral Drugs (2012) (0)
SHORT COMMUNICATION Block of Tat-Mediated Transactivation of Tumor Necrosis Factor b Gene Expression by Polymeric-TAR Decoys (1996) (0)
Combining antiretroviral drugs and immune therapies: an approach to achieve clinical benefit after treatment interruption (2008) (0)
Cellular Immunity and DNA Vaccines for the Treatment of HIV / AIDS (2004) (0)
HIV vaccine to induce cytotoxic T cells recognizing conserved HIV-1/2-epitopes derived from the most frequent HLA types of the human population. (2013) (0)
T cell therapy of CMV and HIV infection (1998) (0)
Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options (2007) (0)
2nd International Symposium on Molecular Diagnostics and Skin Gene Therapy (2003) (0)
Interfering with HIV-1 replication by affecting cellular factors. HIV-1 inhibition by hydroxyurea (1995) (0)

This paper list is powered by the following services:

Other Resources About Julianna Lisziewicz

en.wikipedia.org

What Schools Are Affiliated With Julianna Lisziewicz?

Julianna Lisziewicz is affiliated with the following schools: